|
Mechanism5-HT2A receptor antagonists [+1] |
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.KR |
First Approval Date12 Dec 2024 |
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Laparoscopic Colectomy
The purpose of this phase 3 study is to evaluate the efficacy and safety of VVZ-149 Injections for the treatment of postoperative pain following laparoscopic colectomy.
100 Clinical Results associated with Vivozon Pharmaceutical Co., Ltd.
0 Patents (Medical) associated with Vivozon Pharmaceutical Co., Ltd.
100 Deals associated with Vivozon Pharmaceutical Co., Ltd.
100 Translational Medicine associated with Vivozon Pharmaceutical Co., Ltd.